PRO: Patients With Hepatitis C Virus With Pretreatment Metavir Stage 3 Fibrosis Do Not Require Hepatocellular Carcinoma Surveillance After Sustained Virological Response
Amoah Yeboah‐Korang, Nicole M. Gentile, Claus J. Fimmel – 14 December 2018
Rationing Care: Barriers to Direct‐Acting Antiviral Treatment in Medicaid Treatment Criteria
Phil Waters, Tina Broder – 14 December 2018
Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?
Christian B. Ramers, Stacey B. Trooskin – 14 December 2018
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.
Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes
Baris D. Yildiz – 14 December 2018
Alpha‐Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes
Neil Mehta, Jennifer L. Dodge, John P. Roberts, Ryutaro Hirose, Francis Y. Yao – 13 December 2018 – High alpha‐fetoprotein (AFP) > 1,000 ng/mL is associated with poor outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). A new national policy has been implemented for AFP > 1,000 ng/mL requiring a decrease to < 500 ng/mL before LT, but there is a paucity of data on the optimal AFP threshold before LT.
Combatting Fibrosis: Exosome‐Based Therapies in the Regression of Liver Fibrosis
Li Chen, David A. Brenner, Tatiana Kisseleva – 13 December 2018 – Hepatic fibrosis results from chronic injury and inflammation in the liver and leads to cirrhosis, liver failure, and portal hypertension. Understanding the molecular mechanisms underlying hepatic fibrosis has advanced the prospect of developing therapies for regression of the disease.
Combatting Fibrosis: Exosome‐Based Therapies in the Regression of Liver Fibrosis
Li Chen, David A. Brenner, Tatiana Kisseleva – 13 December 2018 – Hepatic fibrosis results from chronic injury and inflammation in the liver and leads to cirrhosis, liver failure, and portal hypertension. Understanding the molecular mechanisms underlying hepatic fibrosis has advanced the prospect of developing therapies for regression of the disease.